PROFILE-1014

NCT01154140 📎

Regimen

Experimental
crizotinib
Control
pemetrexed+platinum

Population

ALK-positive advanced non-sq NSCLC 1L

Key finding

mPFS 10.9 vs 7.0 mo, HR 0.45 (0.35-0.60); established crizotinib 1L for ALK+

Source: PMID 25470694

Timeline

  • Enrollment start: 2011-01-13 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source